Here's hoping it's right...
"While John Hester says that
one of his to watch is Oncosil..
Code OSL.. (mkt cap $73m)
It reports interim results from a pivotal study in pancreatic cancer in a few days time
Chairman is Chris Roberts [ex Cochlear CEo and SRX Chair]
definitely one to watch.
Before all this Hester rated OSL 2nd to VLA after the SRX takeover.
12 Month rating was $0.41
Add to My Watchlist
What is My Watchlist?
one of his to watch is Oncosil..